Applied Clinical Trials Online13h
API-CAT Trial Shows Reduced-Dose Eliquis Matches Full Dose in Preventing Venous Thromboembolism, Lowers Bleeding Risk in Cancer Patients
The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...
Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Oncology Nursing News8d
Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype
Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...
Applied Clinical Trials Online9d
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...
Stockhouse13d
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical ...
PMLive14d
Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) in adults with oestrogen receptor (ER)-positive, human epidermal growth ...
Investing16d
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook
The company is currently awaiting topline data from the Phase 3 VERITAC-2 trial, which is expected to be released in the first quarter of 2025. This trial is crucial for Arvinas, as it will provide ...
MPR16d
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.